UC San Diego researchers identify rutamycin B as potential treatment for brain-eating amoeba

Discovery of rutamycin B’s potential

Researchers at the University of California, San Diego, have identified a compound called rutamycin B, derived from marine bacteria, that demonstrates rapid effectiveness against Naegleria fowleri, the amoeba responsible for primary amebic meningoencephalitis (PAM). In laboratory tests, rutamycin B killed multiple strains of the amoeba within hours, exhibiting a toxicity level 200–300 times higher against the amoeba than against human cells.

The compound targets an enzyme critical to the amoeba’s energy production, a mechanism distinct from current treatments. This selectivity could reduce the dosage required when combined with existing therapies like amphotericin B, potentially lowering the severe side effects associated with PAM treatment.

Why this matters for drug development

PAM, though rare, remains nearly always fatal, with a mortality rate exceeding 97%. Current treatments are slow-acting and highly toxic, often harming patients as much as the infection itself. Rutamycin B’s rapid action and selective toxicity offer a promising alternative, though further studies—including animal testing—are required before human trials can begin.

The discovery also underscores the potential of marine biotechnology in addressing unmet medical needs. Compounds like rutamycin B, sourced from marine bacteria, may hold solutions for other neglected infectious diseases.

What’s next for rutamycin B

While the lab results are encouraging, the compound must undergo rigorous testing in animal models to assess its safety and efficacy in living organisms. Only after successful animal trials can human clinical trials be considered. The timeline for these steps remains uncertain, but the urgency of addressing PAM adds momentum to the research.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

For biotech founders and pharmaceutical operators, this discovery is a reminder of the untapped potential in marine-derived compounds. Rutamycin B’s rapid efficacy against a deadly pathogen highlights how niche research areas—like marine biotechnology—can yield breakthroughs for high-mortality, low-treatment diseases. The compound’s mechanism of action, targeting the amoeba’s energy production, also suggests opportunities for platform technologies that screen for metabolic vulnerabilities in pathogens. While the path to clinical use is long, the findings could attract interest from investors and collaborators focused on infectious disease innovations.

Related on Lazyfounder

• University of California, San Diego
• More health news